Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
Paul A. Kelly
Abstract
Paul A. Kelly
Abstract
In the paper by Gouzoulis-Mayfrank et al (this issue, pp 719–725)1, the authors provide evidence that even moderate use of the recreational drug methylenedioxymethamphetamine (MDMA) may lead to cognitive decline in otherwise healthy young people. This amphetamine derivative (known widely as ecstasy, XTC, or E, but also as Adam, clarity, or essence) is widely used by young people throughout western Europe and the United States. The popularity of the drug has been enhanced by its close …
OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In the paper by Gouzoulis-Mayfrank et al (this issue, pp 719–725)1, the authors provide evidence that even moderate use of the recreational drug methylenedioxymethamphetamine (MDMA) may lead to cognitive decline in otherwise healthy young people. This amphetamine derivative (known widely as ecstasy, XTC, or E, but also as Adam, clarity, or essence) is widely used by young people throughout western Europe and the United States. The popularity of the drug has been enhanced by its close …
Key concepts: Ecstasy, MDMA, Recreational Drug, Amphetamine, CLARITY, Recreational drug use, Recreational use, Drug